HomeCompareOBLN vs QSR

OBLN vs QSR: Dividend Comparison 2026

OBLN yields 65.57% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OBLN wins by $828.4K in total portfolio value
10 years
OBLN
OBLN
● Live price
65.57%
Share price
$3.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$853.1K
Annual income
$213,279.01
Full OBLN calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — OBLN vs QSR

📍 OBLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOBLNQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OBLN + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OBLN pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OBLN
Annual income on $10K today (after 15% tax)
$5,573.77/yr
After 10yr DRIP, annual income (after tax)
$181,287.16/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, OBLN beats the other by $180,957.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OBLN + QSR for your $10,000?

OBLN: 50%QSR: 50%
100% QSR50/50100% OBLN
Portfolio after 10yr
$438.9K
Annual income
$106,833.45/yr
Blended yield
24.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

OBLN
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Altman Z
-22.4
Piotroski
3/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OBLN buys
0
QSR buys
0
No recent congressional trades found for OBLN or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOBLNQSR
Forward yield65.57%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$853.1K$24.7K
Annual income after 10y$213,279.01$387.88
Total dividends collected$718.9K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusHoldBuy

Year-by-year: OBLN vs QSR ($10,000, DRIP)

YearOBLN PortfolioOBLN Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$17,257$6,557.38$11,038$337.57+$6.2KOBLN
2$29,041$10,575.99$12,156$345.43+$16.9KOBLN
3$47,708$16,633.36$13,359$352.69+$34.3KOBLN
4$76,584$25,536.82$14,654$359.36+$61.9KOBLN
5$120,257$38,311.84$16,045$365.45+$104.2KOBLN
6$184,899$56,223.86$17,539$370.97+$167.4KOBLN
7$278,632$80,790.63$19,143$375.96+$259.5KOBLN
8$411,919$113,782.33$20,863$380.42+$391.1KOBLN
9$597,960$157,206.82$22,708$384.39+$575.3KOBLN
10$853,096$213,279.01$24,685$387.88+$828.4KOBLN

OBLN vs QSR: Complete Analysis 2026

OBLNStock

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.

Full OBLN Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this OBLN vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OBLN vs SCHDOBLN vs JEPIOBLN vs OOBLN vs KOOBLN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.